Literature DB >> 17581611

Lenalidomide as induction therapy before allogeneic stem cell transplantation in a patient with proliferative CMML-2 and del(5q) not involving the EGR1 locus.

U Platzbecker, B Mohr, M von Bonin, M Binder, J Schetelig, G Ehninger, M Bornhäuser.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17581611     DOI: 10.1038/sj.leu.2404811

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  4 in total

1.  Monitoring of donor chimerism in sorted CD34+ peripheral blood cells allows the sensitive detection of imminent relapse after allogeneic stem cell transplantation.

Authors:  Martin Bornhäuser; Uta Oelschlaegel; Uwe Platzbecker; Gesine Bug; Karin Lutterbeck; Michael G Kiehl; Johannes Schetelig; Alexander Kiani; Thomas Illmer; Markus Schaich; Catrin Theuser; Brigitte Mohr; Cornelia Brendel; Axel A Fauser; Stefan Klein; Hans Martin; Gerhard Ehninger; Christian Thiede
Journal:  Haematologica       Date:  2009-11       Impact factor: 9.941

2.  Lenalidomide maintenance after allogeneic HSCT seems to trigger acute graft-versus-host disease in patients with high-risk myelodysplastic syndromes or acute myeloid leukemia and del(5q): results of the LENAMAINT trial.

Authors:  Katja Sockel; Martin Bornhaeuser; Eva Mischak-Weissinger; Rudolf Trenschel; Martin Wermke; Christian Unzicker; Guido Kobbe; Jürgen Finke; Ulrich Germing; Brigitte Mohr; Jochen Greiner; Dietrich Beelen; Christian Thiede; Gerhard Ehninger; Uwe Platzbecker
Journal:  Haematologica       Date:  2012-09       Impact factor: 9.941

3.  Diagnosis and management of chronic myelomonocytic leukemia.

Authors:  Francesco Onida; Miloslav Beran
Journal:  Curr Hematol Malig Rep       Date:  2008-01       Impact factor: 3.952

Review 4.  Chronic myelomonocytic leukemia: Forefront of the field in 2015.

Authors:  Christopher B Benton; Aziz Nazha; Naveen Pemmaraju; Guillermo Garcia-Manero
Journal:  Crit Rev Oncol Hematol       Date:  2015-03-14       Impact factor: 6.312

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.